Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

University of Newcastle upon Tyne describes compounds for preventing DNA damage

Feb. 15, 2022

SAF-248 shows potent activity against DLBCL in vitro and in vivo

Feb. 14, 2022

Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical identify new SOS1 inhibitors

Feb. 14, 2022

FLT3 inhibitors discovered at Cytosinlab Therapeutics

Feb. 14, 2022

Reaction Biology presents new HDAC inhibitors

Feb. 10, 2022

Chinese researchers identify new CRBN modulators

Feb. 10, 2022

IFM Due patents hSTING antagonists for cancer

Feb. 9, 2022

Researchers publish data on VIP-236 as a promising antitumoral agent

Feb. 8, 2022

Navidea sponsors research at Penn to evaluate Tc99m tilmanocept as prognostic marker in glioblastoma

Feb. 8, 2022

Wuhan LL Science and Technology Development presents new ROCK inhibitors

Feb. 8, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...